Effects of lappaconitine hydrobromide on qt interval in patients with paroxysmal atrial fibrillation

Abstract

84 patients aged 40 to 70 years received Holter ECG monitoring to determine the values of QT’interval measurement. All patients were divided into 4 groups: group 1 – 24 healthy patients, group 2 – (n = 24) patients with ischemic heart disease (IHD) without indication to atrial fibrillation (AF), group 3 (n = 20) patients with IHD with AF using amiodarone for prevention of AF at a dose 200 mg/day, 5 days a week, group 4 (n = 16) – patients with IHD with AF using lappaconitine hydrobromide for prevention of AF at a dose of 25 mg 3 times a day. In the groups, QTav. varied from 391.78 ± 6.60 ms (in healthy subjects) to 437.13 ± 7.16 ms (on the top of amiodarone therapy). But despite a significant increase in this parameter in patients with IHD without AF, QTav. interval remained within the normal limits on the top of lappaconitine hydrobromide and amiodarone therapy compared with the healthy subjects group. The QTc interval was recorded from 389.20 ± 9.32 ms (IHD without FP) to 421.88 ± 6.08 ms (on the top of amiodarone therapy) in the groups. This parameter was not significantly different across the groups and remained within the normal limits. The QTd interval spread was from 14.75 ± 2.00 ms (on the top of amiodarone therapy) to 32.50 ± 11.26 ms (on the top of of lappaconitine hydrobromide therapy) in the groups. Despite the fact that this parameter was significantly higher on the top of lappaconitine hydrobromide therapy, it did not go beyond the normal limits either.